-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Gastric cancer is one of the most common malignant tumors in the world.
Gastric cancer is one of the most common malignant tumors in the world.
The study is a single-arm, prospective, multi-center, non-interventional post-marketing observational study.
The study is a single-arm, prospective, multi-center, non-interventional post-marketing observational study.
The study included 687 patients, of which 658 patients met the analysis of the study.
Most patients in the ramucirumab combination therapy group and ramucirumab monotherapy group had adverse events ≥ 1 (combination group: any grade, 479/528; 90.
Common adverse events
At 6 months, 490 (74.
At 6 months, 490 (74.
Proportion and reason of ramucirumab interrupted treatment
The median survival time of single-agent treatment and combination treatment was 5.
The median survival time of single-agent treatment and combination treatment was 5.
subsistence analysis
In summary, this Japanese real-world study shows that the efficacy and safety of ramucirumab in the treatment of advanced gastric cancer are consistent with clinical studies.
In summary, this Japanese real-world study shows that the efficacy and safety of ramucirumab in the treatment of advanced gastric cancer are consistent with clinical studies.
Original source:
Yucherng Chen, Taeko Katayose, Soshi Nagaoka, et al.
Yucherng Chen, Taeko Katayose, Soshi Nagaoka, et al.
A post-marketing observational study of ramucirumab in patients with gastric cancer in Japan.
Gastric Cancer.
2021 May 28.
doi: 10.
1007/s10120-021-01199-0.
Online ahead of print.
Leave a message here
